News

En el marco del Concurso Científico anual de la Real Academia de Medicina y Cirugía de Sevilla, se ha celebrado la entrega del Premio a la investigación en Vejiga Hiperactiva, patrocinado por Gebro Pharma y dotado con 3.000 euros y diploma acreditativo. El trabajo premiado, titulado “Utilidad de la oxibutinina transdérmica en el tratamiento de la vejiga hiperactiva” está liderado […]

leer más

Un año más el Ministerio de Economía ha publicado la resolución del último Plan Profarma (2013-2016), el cual clasifica y califica anualmente a los laboratorios farmacéuticos más destacados por su compromiso con la producción y la I+D+i en España. Una iniciativa que tiene como objetivo fomentar la competitividad del sector en nuestro país y en la que Gebro Pharma cumple […]

read more

Laboratorios Gebro Pharma inicia el año con el lanzamiento de Paxiflas®, una combinación fija de Paracetamol/Tramadol a dosis bajas (Paracetamol 325mg / Tramadol 37,5mg), indicado para el tratamiento sintomático del dolor moderado a intenso, agudo o crónico. Gracias a los mecanismos de acción complementarios de sus dos componentes, el fármaco proporciona un inicio rápido de la acción gracias a paracetamol […]

read more

Gebro Pharma has launched Kentera® in Spain, the only oxybutynin transdermal patch to treat incontinence and other symptoms in adult patients with overactive bladder. Specifically, Kentera® is indicated for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency in adult patients with an overactive bladder. As explained by the head of the Urology Service at the Hospital […]

read more

The Spanish Association of People Affected by Brain Tumours (ASATE); the DACER Foundation, specialized in rehabilitation of brain damage; the Hospital Universitario Ramón y Cajal in Madrid, in collaboration with Laboratorios Gebro Pharma have held a conference this morning because of International Brain Tumour Day with the aim of informing and raising awareness of this pathology and the situation and needs […]

leer más

Laboratorios Gebro Pharma and the Spanish Urology Association have joined forces to work together in the field of urologic pathologies. Specifically, the goal of the agreement signed by Gebro Pharma’s General Director, Sergi Aulinas, and José Manuel Cózar, the President of the Spanish Urological Association, is to develop activities in connection with training, research and innovation in the diagnosis and […]

leer más

Gebro Pharma continues to innovate to improve its patients’ quality of life. The pharmaceutical company has launched Ialuril® Prefill, a new presentation of Ialuril in comfortable prefilled syringes for easier and better handling. Ialuril® Prefill, administered through intravesical route, is a balanced combination of hyaluronate acid, chondroitin sulfate and calcium chloride as excipient, to improve the product’s adhesion to the […]

read more

The Austrian company, Gebro Pharma and the Italian company Recordati, had recently signed an exclusive agreement for distribution, promotion and commercialization of Kentera in Spain. Kentera® is indicated for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder. The urinary incontinence market in Spain has a turnover of […]

read more